Quadria Capital preparing to exit biotech firm

Premium

India and Southeast Asia-focused Quadria Capital is preparing to exit a biotech portfolio firm as deals in the broader pharmaceuticals space gain traction because of the pandemic.    Quadria Capital is preparing to exit its 20% stake in Concord Biotech and has shortlisted Kotak Mahindra Bank and Torreya Partners to run ......